Legend ® (hyaluronate sodium) Injectable Solution

Manufacturer
Boehringer Ingelheim Animal Health USA Inc
Effective date
2025-05-02
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-06-01 02:44:36

Label at a glance#

ProductLegend
Active ingredienthyaluronate sodium
Label structure20 sections

Storage and handling

STORAGE: Store at or below 77°F (25°C). Brief excursions to 104°F (40°C) are permitted.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For intravenous use in horses only

4 mL

SPL UNCLASSIFIED SECTION

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION SECTION

DESCRIPTION:

LEGEND Injectable Solution is a clear, colorless solution of low viscosity. LEGEND Injectable Solution is pyrogen free, sterile and does not contain a preservative. It is administered by intravenous injection.

Hyaluronic acid, the conjugate acid of hyaluronate sodium, is extracted from the capsule of Streptococcus spp. and purified, resulting in a form which is essentially free of protein and nucleic acids.

LEGEND Injectable Solution is supplied in 4 mL (40 mg) vials. Each mL contains 10 mg hyaluronate sodium, 8.5 mg sodium chloride, 0.223 mg sodium phosphate dibasic, and 0.04 mg sodium phosphate monobasic. The pH is adjusted to between 6.5 and 8.0 with sodium hydroxide or hydrochloric acid.

SPL UNCLASSIFIED SECTION

CHEMISTRY:

Hyaluronic acid, a glycosaminoglycan, can exist in the following forms depending upon the chemical environment in which it is found: as the acid, hyaluronic acid; as the sodium salt, sodium hyaluronate (hyaluronate sodium); or as the hyaluronate anion. These terms may be used interchangeably but in all cases, reference is made to the glycosaminoglycan composed of repeating subunits of D-glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulfate or any other glycosaminoglycan.

CLINICAL PHARMACOLOGY SECTION

CLINICAL PHARMACOLOGY:

Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour and the umbilical cord in all mammals. High concentrations of hyaluronic acid are also found in the synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals.

The actual mechanism of action for hyaluronate sodium in the healing of degenerative joint disease is not completely understood. One major function appears to be the regulation of normal cellular constituents. This effect decreases the impact of exudation, enzyme release and subsequent degradation of joint integrity. Additionally, hyaluronate sodium exerts an anti-inflammatory action by inhibiting the movement of granulocytes and macrophages.1

Hyaluronate molecules are long chains which form a filter network interspersed with normal cellular fluids. It is widely accepted that injection directly into the joint pouch enhances the healing of inflamed synovium by restoring lubrication of the joint fluid. This further supplements the visco-elastic properties of normal joint fluid.

VETERINARY INDICATIONS SECTION

INDICATIONS:

LEGEND Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION:

4 mL (40 mg) injected intravenously. Treatment may be repeated at weekly intervals for a total of three treatments.

Use aseptic technique and inject slowly into the jugular vein.

Horses should be given stall rest after treatment before gradually resuming normal activity.

Discard any unused portion of the drug and empty vial after opening.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS:

There are no known contraindications for the use of LEGEND Solution in horses.

RESIDUE WARNING SECTION

RESIDUE WARNING:

Do not use in horses intended for human consumption.

WARNINGS SECTION

HUMAN WARNINGS:

Not for use in humans. Keep this and all other drugs out of reach of children.

WARNINGS SECTION

ANIMAL SAFETY WARNING:

Not for Intra-articular use.

PRECAUTIONS SECTION

PRECAUTIONS:

Radiographic evaluation should be carried out in cases of acute lameness to ensure that the joint is free from serious fracture.

The safety of LEGEND Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.

ADVERSE REACTIONS SECTION

ADVERSE REACTIONS:

No local or systemic side effects were observed in the field studies using LEGEND Injectable Solution.

SPL UNCLASSIFIED SECTION

Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for LEGEND Injectable Solution: Occasional depression, lethargy, and fever.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

SPL UNCLASSIFIED SECTION

EFFECTIVENESS:

Forty-six horses with lameness in either the carpal or fetlock joints were treated intravenously or intra-articularly with LEGEND Injectable Solution in a well-controlled field study conducted at four locations. One, two or three injections were given based on clinical improvement. Overall clinical improvement was judged as excellent or good in 90% of the cases treated intravenously and 96% of those treated intra-articularly with LEGEND Injectable Solution.

SPL UNCLASSIFIED SECTION

ANIMAL SAFETY:

LEGEND Injectable Solution was administered to normal horses at one, three and five times the recommended intra-articular dosage of 20 mg and intravenous dosage of 40 mg. Treatments were given once weekly for nine consecutive weeks (three times the maximum duration). No systemic clinical signs were observed nor were there any adverse effects upon hematology or clinical chemistry parameters. A transient, slight to mild post injection swelling of the joint capsule occurred in some of the animals treated intra-articularly with LEGEND Injectable Solution as it did in the saline treated control horse. No gross or histological lesions were observed in the soft tissues or the surface areas of the treated joint.

STORAGE AND HANDLING SECTION

STORAGE:

Store at or below 77°F (25°C). Brief excursions to 104°F (40°C) are permitted.

HOW SUPPLIED SECTION

HOW SUPPLIED:

LEGEND Injectable Solution is supplied in a carton of six 4 mL (40 mg) bottles.

Approved by FDA under NADA # 140-883

Marketed by: Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096

REFERENCES SECTION

REFERENCE:

1Swanstrom, O.G. 1978. Hyaluronate (hyaluronic acid) and its use, Proc. American Assoc. Equine Pract., 24th annual convention, pp. 345-348.

SPL UNCLASSIFIED SECTION

® LEGEND is a registered trademark and the horse logo is a trademark of

Boehringer Ingelheim Animal Health USA Inc.

© 2019 Boehringer Ingelheim Animal Health USA Inc.

1050-8682-03, Rev. 12-2019

86851091

PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Legend®
(hyaluronate sodium)
Injectable Solution 10 mg/mL

For intravenous use in horses only

6 x 4 mL vials

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDAunderNADA # 140-883

Image of 4 ml Carton
Image of 4 ml Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
891140Legend 10 MG/ML Injectable SolutionPSN2
562106sodium hyaluronate 10 MG/mL Injectable SolutionPSN2
891140sodium hyaluronate 10 MG/ML Injectable Solution [Legend]SBD2
562106sodium hyaluronate 10 MG/ML Injectable SolutionSCD2
891140Legend 10 MG/ML Injectable SolutionSY2
891140Legend 20 MG per 2 ML Injectable SolutionSY2
891140Legend 40 MG per 4 ML Injectable SolutionSY2

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0010-3141-01Legend4 mL in 1 BOTTLEINJECTION, SOLUTION42
0010-3141-01Legend6 in 1 CARTONINJECTION, SOLUTION62

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0010-3141LEGEND (HYALURONATE SODIUM) INJECTION, SOLUTION [BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC]22 package rows20250504_fe08dc5c-e1d3-44ca-837b-4ede07402771.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0010-31410010-3141-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CELISTAR MICRONEEDLING INFUSIONHYALURONATE SODIUMGuangdong Outeli Biotechnology Co., Ltd.53de46a7-3947-70a7-e063-6294a90ab8292026-06-09WarningsName fallback
generic name: HYALURONATE SODIUM

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.